FGF21-based pharmacotherapy – potential utility for metabolic disorders
Abstract
Currently available therapies for diabetes or obesity produce modest efficacy and are usually used in combination with agents targeting cardiovascular risk factors. Fibroblast growth factor 21 (FGF21) is a circulating protein with pleiotropic metabolic actions; pharmacological doses of FGF21 produce anti-diabetic, lipid-lowering, and weight-reducing effects in rodents. Several potential benefits have translated to non-human primates and obese humans with type 2 diabetes (T2D). Accumulating results point to a specific receptor complex and actions in adipose tissue, liver, and brain; several pathways lead to enhanced fatty acid oxidation, increased insulin sensitivity, and augmented energy expenditure. A range of strategies are being explored to derive potent, safe, and convenient therapies which could potentially represent novel approaches to prevent and treat a variety of metabolic disorders.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Multiple FGF21 analogs have been developed or are in development for treating metabolic disease.
“Multiple FGF21 analogs have been developed or are in development for treating metabolic disease (44).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [44]
Cites
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · see citing works
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504 · see citing works
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495 · see citing works
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis
Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478 · see citing works
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151 · see citing works
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031 · see citing works
Self-citationThe effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · see citing works
Self-citationObesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., & Maratos-Flier, E. (2010) · Diabetes · doi:10.2337/db10-0193 · Cited by 830 · see citing works
Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans
Lee, P., Linderman, J. D., Smith, S., Brychta, R. J., Wang, J., Idelson, C., Perron, R. M., Werner, C. D., Phan, G. Q., Kammula, U. S., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.017 · Cited by 802 · see citing works
Kim, K. H., Jeong, Y. T., Oh, H., Kim, S. H., Cho, J. M., Kim, Y.-N., Kim, S. S., Kim, D. H., Hur, K. Y., Kim, H. K., et al. (2013) · Nature Medicine · doi:10.1038/nm.3014 · Cited by 774 · see citing works
Kurosu, H., Choi, M., Ogawa, Y., Dickson, A. S., Goetz, R., Eliseenkova, A. V., Mohammadi, M., Rosenblatt, K. P., Kliewer, S. A., & Kuro-o, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704165200 · Cited by 748 · see citing works
The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738 · see citing works
Potthoff, M. J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Mohammadi, M., Finck, B. N., Mangelsdorf, D. J., Kliewer, S. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904187106 · Cited by 704 · see citing works
Lin, Z., Tian, H., Lam, K. S. L., Lin, S., Hoo, R. C. L., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.005 · Cited by 691 · see citing works
βKlotho is required for metabolic activity of fibroblast growth factor 21
Ogawa, Y., Kurosu, H., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Goetz, R., Eliseenkova, A. V., Mohammadi, M., & Kuro-o, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701600104 · Cited by 617 · see citing works
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela–Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez–Chantar, M. L., & Maratos–Flier, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.054 · Cited by 607 · see citing works
Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK–SIRT1–PGC-1α pathway
Chau, M. D. L., Gao, J., Yang, Q., Wu, Z., & Gromada, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006962107 · Cited by 548 · see citing works
FGF21 regulates metabolism and circadian behavior by acting on the nervous system
Bookout, A. L., de Groot, M. H. M., Owen, B. M., Lee, S., Gautron, L., Lawrence, H. L., Ding, X., Elmquist, J. K., Takahashi, J. S., Mangelsdorf, D. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3249 · Cited by 545 · see citing works
Dutchak, P. A., Katafuchi, T., Bookout, A. L., Choi, J. H., Yu, R. T., Mangelsdorf, D. J., & Kliewer, S. A. (2012) · Cell · doi:10.1016/j.cell.2011.11.062 · Cited by 537 · see citing works
An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice
Holland, W., Adams, A., Brozinick, J., Bui, H., Miyauchi, Y., Kusminski, C., Bauer, S., Wade, M., Singhal, E., Cheng, C. C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.019 · Cited by 525 · see citing works
Gälman, C., Lundåsen, T., Kharitonenkov, A., Bina, H. A., Eriksson, M., Hafström, I., Dahlin, M., Åmark, P., Angelin, B., & Rudling, M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.06.014 · Cited by 512 · see citing works
Wente, W., Efanov, A. M., Brenner, M. B., Kharitonenkov, A., Koster, A. M., Sandusky, G. E., Sewing, S., Treinies, I., Zitzer, H., & Gromada, J. (2006) · Diabetes · doi:10.2337/db05-1435 · Cited by 497 · see citing works
Wei, W., Dutchak, P. A., Wang, X., Ding, X., Wang, X., Bookout, A. L., Goetz, R., Mohammadi, M., Gerard, R. D., Dechow, P. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200797109 · Cited by 426 · see citing works
The starvation hormone, fibroblast growth factor-21, extends lifespan in mice
Zhang, Y., Xie, Y., Berglund, E. D., Coate, K. C., He, T. T., Katafuchi, T., Xiao, G., Potthoff, M. J., Wei, W., Wan, Y., et al. (2012) · eLife · doi:10.7554/elife.00065 · Cited by 420 · see citing works
Inhibition of Growth Hormone Signaling by the Fasting-Induced Hormone FGF21
Inagaki, T., Lin, V. Y., Goetz, R., Mohammadi, M., Mangelsdorf, D. J., & Kliewer, S. A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.05.006 · Cited by 409 · see citing works
βKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and Metabolism
Ding, X., Boney-Montoya, J., Owen, B. M., Bookout, A. L., Coate, K. C., Mangelsdorf, D. J., & Kliewer, S. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.08.002 · Cited by 403 · see citing works
Fibroblast Growth Factor 21-Deficient Mice Demonstrate Impaired Adaptation to Ketosis
Badman, M. K., Koester, A., Flier, J. S., Kharitonenkov, A., & Maratos-Flier, E. (2009) · Endocrinology · doi:10.1210/en.2009-0532 · Cited by 362 · see citing works
Life Extension in the Dwarf Mouse
Bartke, A., & Brown‐Borg, H. M. (2004) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(04)63006-7 · Cited by 354 · see citing works
Hotta, Y., Nakamura, H., Konishi, M., Murata, Y., Takagi, H., Matsumura, S., Inoue, K., Fushiki, T., & Itoh, N. (2009) · Endocrinology · doi:10.1210/en.2009-0119 · Cited by 352 · see citing works
Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.-C., Graham, M., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00348.2009 · Cited by 340 · see citing works
FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho
Kharitonenkov, A., Dunbar, J. D., Bina, H. A., Bright, S. W., Moyers, J. S., Zhang, C., Ding, L., Micanovic, R., Mehrbod, S. F., Knierman, M. D., et al. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21357 · Cited by 329 · see citing works
Berglund, E. D., Li, C. Y., Bina, H. A., Lynes, S. E., Michael, M. D., Shanafelt, A. B., Kharitonenkov, A., & Wasserman, D. H. (2009) · Endocrinology · doi:10.1210/en.2009-0221 · Cited by 297 · see citing works
Muise, E. S., Azzolina, B., Kuo, D. W., El-Sherbeini, M., Tan, Y., Yuan, X., Mu, J., Thompson, J. R., Berger, J. P., & Wong, K. K. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.044826 · Cited by 294 · see citing works
Acute Exercise Induces FGF21 Expression in Mice and in Healthy Humans
Kim, K. H., Kim, S. H., Min, Y.-K., Yang, H.-M., Lee, J.-B., & Lee, M.-S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063517 · Cited by 290 · see citing works
Sarruf, D. A., Thaler, J. P., Morton, G. J., German, J. P., Fischer, J. D., Ogimoto, K., & Schwartz, M. W. (2010) · Diabetes · doi:10.2337/db09-1878 · Cited by 287 · see citing works
The fasting polypeptide FGF21 can enter brain from blood
Hsuchou, H., Pan, W., & Kastin, A. J. (2007) · Peptides · doi:10.1016/j.peptides.2007.10.007 · Cited by 280 · see citing works
The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue
Adams, A. C., Yang, C., Coskun, T., Cheng, C. C., Gimeno, R. E., Luo, Y., & Kharitonenkov, A. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2012.08.007 · Cited by 266 · see citing works
Self-citationAdiponectin, driver or passenger on the road to insulin sensitivity?
Ye, R., & Scherer, P. E. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.04.001 · Cited by 251 · see citing works
Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes · doi:10.2337/db12-1116 · Cited by 245 · see citing works
FGF21 contributes to neuroendocrine control of female reproduction
Owen, B. M., Bookout, A. L., Ding, X., Lin, V. Y., Atkin, S. D., Gautron, L., Kliewer, S. A., & Mangelsdorf, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3250 · Cited by 230 · see citing works
Integrated Regulation of Hepatic Metabolism by Fibroblast Growth Factor 21 (FGF21) in Vivo
Fisher, F. M., Estall, J. L., Adams, A. C., Antonellis, P. J., Bina, H. A., Flier, J. S., Kharitonenkov, A., Spiegelman, B. M., & Maratos–Flier, E. (2011) · Endocrinology · doi:10.1210/en.2011-0281 · Cited by 229 · see citing works
Zheng, C., Khoo, C., Furtado, J., & Sacks, F. M. (2010) · Circulation · doi:10.1161/circulationaha.109.875807 · Cited by 223 · see citing works
Foltz, I. N., Hu, S., King, C., Wu, X., Yang, C., Wang, W., Weiszmann, J., Stevens, J., Chen, J. S., Nuanmanee, N., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004690 · Cited by 211 · see citing works
Fibroblast Growth Factor-21 Is Induced in Human Skeletal Muscles by Hyperinsulinemia
Hojman, P., Pedersen, M., Nielsen, A. R., Krogh-Madsen, R., Yfanti, C., Åkerstrom, T., Nielsen, S., & Pedersen, B. K. (2009) · Diabetes · doi:10.2337/db09-0713 · Cited by 198 · see citing works
Molecular determinants of FGF‐21 activity—synergy and cross‐talk with PPARγ signaling
Moyers, J. S., Shiyanova, T. L., Mehrbod, F., Dunbar, J. D., Noblitt, T. W., Otto, K. A., Reifel-Miller, A. E., & Kharitonenkov, A. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20847 · Cited by 193 · see citing works
Wu, A.-L., Kolumam, G., Stawicki, S., Chen, Y., Li, J., Zavala-Solorio, J., Phamluong, K., Feng, B., Li, L., Marsters, S., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002669 · Cited by 184 · see citing works
Ge, X., Chen, C., Hui, X. H., Wang, Y., Lam, K. S. L., & Xu, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.248591 · Cited by 181 · see citing works
FGF21 Requires βklotho to Act In Vivo
Adams, A. C., Cheng, C. C., Coskun, T., & Kharitonenkov, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049977 · Cited by 181 · see citing works
High Plasma Level of Fibroblast Growth Factor 21 Is an Independent Predictor of Type 2 Diabetes
Chen, C., Cheung, B. M. Y., Tso, A. W. K., Wang, Y., Law, L. S., Ong, K. L., Wat, N. M. S., Xu, A., & Lam, K. S. L. (2011) · Diabetes Care · doi:10.2337/dc11-0294 · Cited by 181 · see citing works
Fibroblast Growth Factor 21 Reduces the Severity of Cerulein-Induced Pancreatitis in Mice
Johnson, C. L., Weston, J. Y., Chadi, S. A., Fazio, E. N., Huff, M. W., Kharitonenkov, A., Köester, A., & Pin, C. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.064 · Cited by 180 · see citing works
Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
Yang, C., Jin, C., Li, X., Wang, F., McKeehan, W. L., & Luo, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033870 · Cited by 173 · see citing works
LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys
Adams, A. C., Halstead, C. A., Hansen, B. C., Irizarry, A. R., Martin, J. A., Myers, S. R., Reynolds, V. L., Smith, H. W., Wroblewski, V. J., & Kharitonenkov, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065763 · Cited by 169 · see citing works
Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319
Kharitonenkov, A., Beals, J. M., Micanovic, R., Strifler, B. A., Rathnachalam, R., Wroblewski, V. J., Li, S., Köester, A., Ford, A. M., Coşkun, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058575 · Cited by 168 · see citing works
Self-citationHecht, R. I., Li, Y., Sun, J., Belouski, E., Hall, M. P., Hager, T., Yie, J., Wang, W., Winters, D., Smith, S. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049345 · Cited by 166 · see citing works
Fibroblast growth factor 21 is induced by endoplasmic reticulum stress
Schaap, F. G., Kremer, A. E., Lamers, W. H., Jansen, P. L. M., & Gaemers, I. C. (2012) · Biochimie · doi:10.1016/j.biochi.2012.10.019 · Cited by 164 · see citing works
Mu, J., Pinkstaff, J. K., Li, Z., Skidmore, L. K., Li, N., Myler, H. A., Dallas-Yang, Q., Hays, A. A., Yao, J., Bussell, S., et al. (2011) · Diabetes · doi:10.2337/db11-0838 · Cited by 162 · see citing works
Müller, T. D., Sullivan, L. M., Habegger, K., Yi, C., Kabra, D., Grant, E., Ottaway, N., Krishna, R., Holland, J., Hembree, J., et al. (2012) · Journal of Peptide Science · doi:10.1002/psc.2408 · Cited by 156 · see citing works
Christodoulides, C., Dyson, P., Sprecher, D., Tsintzas, K., & Karpe, F. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0111 · Cited by 153 · see citing works
FGF21 N‐ and C‐termini play different roles in receptor interaction and activation
Yie, J., Hecht, R., Patel, J., Stevens, J., Wang, W., Hawkins, N., Steavenson, S., Smith, S., Winters, D., Fisher, S., et al. (2009) · FEBS Letters · doi:10.1016/j.febslet.2008.11.023 · Cited by 149 · see citing works
Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys
Véniant, M. M., Komorowski, R., Chen, P., Stanislaus, S., Winters, K., Hager, T., Zhou, L., Wada, R., Hecht, R. I., & Xu, J. (2012) · Endocrinology · doi:10.1210/en.2012-1211 · Cited by 147 · see citing works
Relevant use of Klotho in FGF19 subfamily signaling system in vivo
Tomiyama, K.-I., Maeda, R., Urakawa, I., Yamazaki, Y., Tanaka, T., Ito, S., Nabeshima, Y., Tomita, T., Odori, S., Hosoda, K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913986107 · Cited by 143 · see citing works
Fibroblast Growth Factor 21 (FGF21) in Human Cerebrospinal Fluid
Tan, B. K., Hallschmid, M., Adya, R., Kern, W., Lehnert, H., & Randeva, H. S. (2011) · Diabetes · doi:10.2337/db11-0672 · Cited by 129 · see citing works
Fibroblast Growth Factor 21 Predicts the Metabolic Syndrome and Type 2 Diabetes in Caucasians
Bobbert, T., Schwarz, F., Fischer‐Rosinsky, A., Pfeiffer, A. F. H., Möhlig, M., Mai, K., & Spranger, J. (2012) · Diabetes Care · doi:10.2337/dc12-0703 · Cited by 125 · see citing works
Huang, J., Ishino, T., Chen, G., Rolzin, P., Osothprarop, T. F., Retting, K., Li, L., Jin, P., Matin, M. J., Huyghe, B., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204420 · Cited by 121 · see citing works
Distinct Changes in Serum Fibroblast Growth Factor 21 Levels in Different Subtypes of Diabetes
Xiao, Y., Xu, A., Law, L. S., Chen, C., Li, H., Li, X., Yang, L., Liu, S., Zhou, Z., & Lam, K. S. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1930 · Cited by 102 · see citing works
Yie, J., Wang, W., Deng, L., Tam, L., Stevens, J., Chen, M. M., Li, Y., Xu, J., Lindberg, R., Hecht, R., et al. (2012) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2012.01325.x · Cited by 99 · see citing works
Leng, Y., Wang, Z., Tsai, L.-K., Leeds, P. R., Fessler, E. B., Wang, J., & Chuang, D. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.192 · Cited by 96 · see citing works
Wu, S., Levenson, A. E., Kharitonenkov, A., & Luca, F. D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.343707 · Cited by 94 · see citing works
Arafat, A. M., Kaczmarek, P., Skrzypski, M., Pruszyńska‐Oszmałek, E., Kolodziejski, P. A., Szczepankiewicz, D., Sassek, M., Wojciechowicz, T., Wiedenmann, B. J., Pfeiffer, A. F. H., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2803-y · Cited by 90 · see citing works
Fine tuning of hepcidin expression by positive and negative regulators
Muckenthaler, M. U. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.06.009 · Cited by 83 · see citing works
Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones
Adams, A. C., Coşkun, T., Cheng, C., O’Farrell, L. S., DuBois, S. L., & Kharitonenkov, A. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.05.005 · Cited by 75 · see citing works
Plasma FGF21 displays a circadian rhythm during a 72‐h fast in healthy female volunteers
Andersen, B., Beck‐Nielsen, H., & Højlund, K. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04084.x · Cited by 74 · see citing works
Hager, T., Spahr, C. S., Xu, J., Salimi-Moosavi, H., & Hall, M. P. (2013) · Analytical Chemistry · doi:10.1021/ac303203y · Cited by 62 · see citing works
Polyethylene Glycol Modified FGF21 Engineered to Maximize Potency and Minimize Vacuole Formation
Xu, J., Bussiere, J. L., Yie, J., Sickmier, E. A., An, P., Belouski, E., Stanislaus, S., & Walker, K. W. (2013) · Bioconjugate Chemistry · doi:10.1021/bc300603k · Cited by 61 · see citing works
FGF21 Can Be Mimicked In Vitro and In Vivo by a Novel Anti-FGFR1c/β-Klotho Bispecific Protein
Smith, R. J., Duguay, A. N., Bakker, A., Li, P., Weiszmann, J., Thomas, M. R., Alba, B. M., Wu, X., Gupte, J., Li, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061432 · Cited by 59 · see citing works
Physiological modulation of circulating FGF21: relevance of free fatty acids and insulin
Mai, K., Bobbert, T., Groth, C., Aßmann, A., Meinus, S., Kraatz, J., Andres, J., Arafat, A. M., Pfeiffer, A. F. H., Möhlig, M., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00020.2010 · Cited by 58 · see citing works
Muise, E. S., Souza, S., Chi, A., Tan, Y., Zhao, X., Liu, F., Dallas-yang, Q., Wu, M., Sarr, T., Zhu, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073011 · Cited by 57 · see citing works
Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans?
Lee, P., Linderman, J. D., Smith, S. M., Brychta, R. J., Perron, R., Idelson, C. R., Werner, C., Chen, K. Y., & Celi, F. S. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2464-9 · Cited by 55 · see citing works
Ge, H., Baribault, H., Vonderfecht, S. L., Lemon, B. D., Weiszmann, J., Gardner, J., Lee, K. J., Gupte, J., Mookherjee, P., Wang, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033603 · Cited by 43 · see citing works
Camacho, R. C., Zafian, P., Achanfuo-Yeboah, J., Manibusan, A., & Berger, J. P. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.06.023 · Cited by 38 · see citing works
Heilbronn, L. K., Campbell, L. V., Xu, A., & Samocha‐Bonet, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078864 · Cited by 36 · see citing works
Fisher, F. M., & Maratos–Flier, E. (2013) · Nature Medicine · doi:10.1038/nm.3058 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028 · see citing works
Understanding the Physiology of FGF21
Fisher, F. M., & Maratos-Flier, E. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105339 · Cited by 912 · see citing works
Targeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678 · see citing works
Talukdar, S., Zhou, Y., Li, D., Rossulek, M., Dong, J., Somayaji, V., Weng, Y., Clark, R., Lanba, A., Owen, B. M., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.001 · Cited by 496 · see citing works
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424 · see citing works
DRP1-mediated mitochondrial shape controls calcium homeostasis and muscle mass
Favaro, G., Romanello, V., Varanita, T., Andrea Desbats, M., Morbidoni, V., Tezze, C., Albiero, M., Canato, M., Gherardi, G., De Stefani, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10226-9 · Cited by 398 · see citing works
FGF21 Regulates Sweet and Alcohol Preference
Talukdar, S., Owen, B. M., Song, P., Hernandez, G., Zhang, Y., Zhou, Y., Scott, W. T., Paratala, B., Turner, T., Smith, A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.008 · Cited by 342 · see citing works
Schlein, C., Talukdar, S., Heine, M., Fischer, A. W., Krott, L. M., Nilsson, S. K., Brenner, M. B., Heeren, J., & Scheja, L. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.006 · Cited by 252 · see citing works
The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis
Herman, M. A., & Samuel, V. T. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.06.005 · Cited by 249 · see citing works
Fructose ingestion acutely stimulates circulating FGF21 levels in humans
Dushay, J. R., Toschi, E., Mitten, E. K., Fisher, F. M., Herman, M. A., & Maratos-Flier, E. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.09.008 · Cited by 233 · see citing works
Jeremic, N., Chaturvedi, P., & Tyagi, S. C. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25450 · Cited by 211 · see citing works
Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis
BonDurant, L. D., & Potthoff, M. J. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064800 · Cited by 222 · see citing works
A liver stress-endocrine nexus promotes metabolic integrity during dietary protein dilution
Maida, A., Zota, A., Sjøberg, K. A., Schumacher, J., Sijmonsma, T. P., Pfenninger, A., Christensen, M. M., Gantert, T., Fuhrmeister, J., Rothermel, U., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85946 · Cited by 170 · see citing works
Gómez‐Ambrosi, J., Gallego-Escuredo, J. M., Catalán, V., Rodrı́guez, A., Domingo, P., Moncada, R., Valentí, V., Salvador, J., Giralt, M., Villarroya, F., et al. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.04.027 · Cited by 168 · see citing works
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Dunshee, D. R., Bainbridge, T. W., Kljavin, N. M., Zavala-Solorio, J., Schroeder, A. C., Chan, R., Corpuz, R., Wong, M., Zhou, W., Deshmukh, G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710582 · Cited by 158 · see citing works
Wu, L., Mo, W., Feng, J., Li, J., Yu, Q., Li, S., Zhang, J., Chen, K., Ji, J., Dai, W., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15099 · Cited by 151 · see citing works
Kim, A. M., Somayaji, V. R., Dong, J. Q., Rolph, T. P., Weng, Y., Chabot, J. R., Gropp, K. E., Talukdar, S., & Calle, R. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13023 · Cited by 145 · see citing works
Metabolic Targets in Nonalcoholic Fatty Liver Disease
Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 142 · see citing works
Fibroblast Growth Factor Signaling in Metabolic Regulation
Nies, V. J. M., Sancar, G., Liu, W., van Zutphen, T., Struik, D., Yu, R. T., Atkins, A. R., Evans, R. M., Jonker, J. W., & Downes, M. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00193 · Cited by 135 · see citing works
Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease
Luo, Y., & Lin, H. (2020) · Immunity Inflammation and Disease · doi:10.1002/iid3.391 · Cited by 127 · see citing works
Mechanisms by Which Skeletal Muscle Myokines Ameliorate Insulin Resistance
Balakrishnan, R., & Thurmond, D. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094636 · Cited by 132 · see citing works
Circulating FGF21 proteolytic processing mediated by fibroblast activation protein
Zhen, E. Y., Jin, Z., Ackermann, B. L., Thomas, M. K., & Gutierrez, J. A. (2016) · Biochemical Journal · doi:10.1042/bj20151085 · Cited by 123 · see citing works
Fibroblast growth factor 21: a regulator of metabolic disease and health span
Xie, T., & Leung, P. S. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00101.2017 · Cited by 121 · see citing works
Regulation of longevity by FGF21: interaction between energy metabolism and stress responses
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.05.004 · Cited by 121 · see citing works
FGF21 activates AMPK signaling: impact on metabolic regulation and the aging process
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1477-1 · Cited by 117 · see citing works
FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties
Kharitonenkov, A., & DiMarchi, R. D. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.09.007 · Cited by 114 · see citing works
Hepatokines: unlocking the multi-organ network in metabolic diseases
Iroz, A., Couty, J.-P., & Postic, C. (2015) · Diabetologia · doi:10.1007/s00125-015-3634-4 · Cited by 111 · see citing works
Singhal, G., Fisher, F. M., Chee, M. J. S., Tan, T. G., Ouaamari, A. E., Adams, A. C., Najarían, R. M., Kulkarni, R., Benoist, C. O., Flier, J. S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148252 · Cited by 112 · see citing works
Caputo, T., Gilardi, F., & Desvergne, B. (2017) · FEBS Letters · doi:10.1002/1873-3468.12742 · Cited by 111 · see citing works
Dong, J. Q., Rossulek, M. I., Somayaji, V. R., Baltrukonis, D. J., Liang, Y., Hudson, K. J., Hernandez‐Illas, M., & Calle, R. A. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12676 · Cited by 100 · see citing works
Bao, L., Yin, J., Gao, W., Wang, Q., Yao, W., & Gao, X.-D. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14383 · Cited by 83 · see citing works
Han, X., Alameh, M., Gong, N., Xue, L., Ghattas, M., Bojja, G., Xu, J., Zhao, G., Warzecha, C. C., Padilla, M. S., et al. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01557-2 · Cited by 96 · see citing works
Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges
Martínez‐Garza, Ú., Torres‐Oteros, D., Yarritu, A., Marrero, P. F., Haro, D., & Relat, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194692 · Cited by 87 · see citing works
The significance of beige and brown fat in humans
Kiefer, F. W. (2017) · Endocrine Connections · doi:10.1530/ec-17-0037 · Cited by 79 · see citing works
Mechanisms linking adipose tissue inflammation to cardiac hypertrophy and fibrosis
Anthony, S., Guarnieri, A., Gozdiff, A., Helsley, R. N., Owens, A. P., & Tranter, M. (2019) · Clinical Science · doi:10.1042/cs20190578 · Cited by 81 · see citing works
Han, X., Xu, J., Xu, Y., Alameh, M., Xue, L., Gong, N., El-Mayta, R. D., Palanki, R., Warzecha, C. C., Zhao, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45537-z · Cited by 83 · see citing works
Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis
Zhou, B., Luo, Y., Ji, N., Hu, C., & Lu, Y. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00627-4 · Cited by 75 · see citing works
Xiao, J., Bei, Y., Liu, J., Dimitrova‐Shumkovska, J., Kuang, D., Zhou, Q., Li, J., Yang, Y., Xiang, Y., Wang, F., et al. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12733 · Cited by 75 · see citing works
Target acquired: Selective autophagy in cardiometabolic disease
Evans, T. D., Sergin, I., Zhang, X., & Razani, B. (2017) · Science Signaling · doi:10.1126/scisignal.aag2298 · Cited by 73 · see citing works
Matar, D. B., Zhra, M., Nassar, W. K., Altemyatt, H., Naureen, A., Abotouk, N., Elahi, M. A., & Aljada, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1592683 · Cited by 80 · see citing works
Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
Zhang, J., & Li, Y. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00168 · Cited by 70 · see citing works
Weng, Y., Chabot, J., Bernardo, B. L., Yan, Q., Zhu, Y., Brenner, M. B., Vage, C., Logan, A., Calle, R. A., & Talukdar, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119104 · Cited by 67 · see citing works
FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans
Samms, R. J., Lewis, J. E., Norton, L., Stephens, F. B., Gaffney, C. J., Butterfield, T., Smith, D. P., Cheng, C. C., Perfield, J. W., Adams, A. C., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01257 · Cited by 65 · see citing works
Ruiz, J. R., Martínez‐Téllez, B., Sánchez‐Delgado, G., Osuna‐Prieto, F. J., Rensen, P. C. N., & Boon, M. R. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.07.002 · Cited by 64 · see citing works
The Impact of Organokines on Insulin Resistance, Inflammation, and Atherosclerosis
Choi, K. M. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.1.1 · Cited by 62 · see citing works
Yano, K., Yamaguchi, K., Seko, Y., Okishio, S., Ishiba, H., Tochiki, N., Takahashi, A., Kataoka, S., Okuda, K., Liu, Y. X., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00680-9 · Cited by 63 · see citing works
Laeger, T., Baumeier, C., Wilhelmi, I., Würfel, J., Kamitz, A., & Schürmann, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4389-x · Cited by 59 · see citing works
Heianza, Y., Ma, W., Huang, T., Wang, T., Zheng, Y., Smith, S. R., Bray, G. A., Sacks, F. M., & Qi, L. (2016) · Diabetes Care · doi:10.2337/dc16-1111 · Cited by 59 · see citing works
Ghoshal, S., Zhu, Q., Asteian, A., Lin, H., Xu, H., Ernst, G. E., Barrow, J. C., Xu, B., Cameron, M. D., Kamenecka, T. M., et al. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.08.008 · Cited by 58 · see citing works
Zhang, H., Zhang, W., Yun, D., Li, L., Zhao, W., Li, Y., Liu, X., & Liu, Z. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108403 · Cited by 59 · see citing works
Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
Connolly, J. J., Ooka, K., & Lim, J. K. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00056 · Cited by 58 · see citing works
Inagaki, T. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00147 · Cited by 55 · see citing works
Peng, X., Gennemark, P., O’Mahony, G., & Bartesaghi, S. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00174 · Cited by 49 · see citing works
Kim, J. H., Bae, K., Choi, Y. ‐., Go, Y., Choe, M., Jeon, Y. ‐., Lee, H.-M., Koo, S., Perfield, J. W., Harris, R. A., et al. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12408 · Cited by 49 · see citing works
Chou, S., Ajoy, R., Changou, C. A., Hsieh, Y.-T., Wang, Y.-K., & Hoffer, B. J. (2016) · Scientific Reports · doi:10.1038/srep37659 · Cited by 49 · see citing works
Bernardo, B. L., Lu, M. M., Bandyopadhyay, G. K., Li, P., Zhou, Y., Huang, J. S., Levin, N., Tomás, E., Calle, R. A., Erion, D. M., et al. (2015) · Scientific Reports · doi:10.1038/srep11382 · Cited by 46 · see citing works
Loyd, C., Magrisso, I. J., Haas, M., Balusu, S., Krishna, R., Itoh, N., Sandoval, D. A., Pérez–Tilve, D., Obici, S., & Habegger, K. M. (2016) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00456.2016 · Cited by 46 · see citing works
Sandoval, V., Femenias, A., Martínez‐Garza, Ú., Sanz‐Lamora, H., Castagnini, J. M., Quifer‐Rada, P., Lamuela-Raventós, R. M., Marrero, P. F., Haro, D., & Relat, J. (2019) · Antioxidants · doi:10.3390/antiox8090360 · Cited by 46 · see citing works
Man, A. W. C., Xia, N., & Li, H. (2020) · Antioxidants · doi:10.3390/antiox9100968 · Cited by 48 · see citing works
Stemmer, K., Zani, F., Habegger, K. M., Neff, C., Kotzbeck, P., Bauer, M., Yalamanchilli, S., Azad, A., Lehti, M., Martins, P. J. F., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3668-7 · Cited by 44 · see citing works
Brown adipose tissue: The heat is on the heart
Thoonen, R., Hindle, A. G., & Scherrer‐Crosbie, M. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00698.2015 · Cited by 44 · see citing works
Xu, X., Krumm, C. S., So, J., Bare, C. J., Holman, C. D., Gromada, J., Cohen, D. E., & Lee, A. (2018) · Hepatology · doi:10.1002/hep.30060 · Cited by 43 · see citing works
Zhang, J., & Li, Y. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.007 · Cited by 42 · see citing works
FGF21 ameliorates the neurocontrol of blood pressure in the high fructose-drinking rats
He, J., Zhao, M., Xia, J.-J., Guan, J., Liu, Y., Wang, L.-Q., Song, D.-X., Qu, M.-Y., Zuo, M., Wen, X., et al. (2016) · Scientific Reports · doi:10.1038/srep29582 · Cited by 40 · see citing works
Browning and thermogenic programing of adipose tissue
Kiefer, F. W. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.09.003 · Cited by 40 · see citing works
McKeown, N. M., Dashti, H. S., Ma, J., Haslam, D. E., Jong, J. C. K., Smith, C. E., Tanaka, T., Graff, M., Lemaître, R. N., Rybin, D. V., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4475-0 · Cited by 40 · see citing works
Fibroblast growth factor 21 has no direct role in regulating fertility in female mice
Singhal, G., Douris, N., Fish, A. J., Zhang, X., Adams, A. C., Flier, J. S., Pissios, P., & Maratos-Flier, E. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.010 · Cited by 38 · see citing works
Liver Brain Interactions: Focus on FGF21 a Systematic Review
Prida, E., Álvarez-Delgado, S., Pérez-Lois, R., Soto-Tielas, M., Estany‐Gestal, A., Fernø, J., Seoane, L. M., Quiñones, M., & Al–Massadi, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113318 · Cited by 39 · see citing works
Fève, B., Bastard, C., Fellahi, S., Bastard, J., & Capeau, J. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.01.001 · Cited by 38 · see citing works
Biomarkers of Metabolic Syndrome: Biochemical Background and Clinical Significance
Robberecht, H. J., & Hermans, N. (2016) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0113 · Cited by 37 · see citing works
Morita, M., Siddiqui, N., Katsumura, S., Rouya, C., Larsson, O. S., Nagashima, T., Hekmatnejad, B., Takahashi, A., Kiyonari, H., Zang, M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816023116 · Cited by 37 · see citing works
Li, S., Zou, T., Chen, J., Li, J., & You, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.033 · Cited by 37 · see citing works
Nutritional Ketosis as a Potential Treatment for Alcohol Use Disorder
Mahajan, V. R., Elvig, S. K., Vendruscolo, L. F., Koob, G. F., Darcey, V. L., King, M. T., Kranzler, H. R., Volkow, N. D., & Wiers, C. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.781668 · Cited by 34 · see citing works
Modulation of energy balance by fibroblast growth factor 21
Ramos, D. C., & Aguilar-Salinas, C. A. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0023 · Cited by 34 · see citing works
Nguyen, A. N., Song, J.-A., Nguyen, M. T., Do, B. H., Kwon, G. G., Park, S. S., Yoo, J., Jang, J., Jin, J., Osborn, M. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16167-x · Cited by 33 · see citing works
Weng, Y., Ishino, T., Sievers, A., Talukdar, S., Chabot, J., Tam, A. S. P., Duan, W., Kerns, K. M., Sousa, E. A., He, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22456-w · Cited by 33 · see citing works
Brown Adipose Tissue: A Human Perspective
Boon, M. R., & Lichtenbelt, W. D. V. M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_11 · Cited by 33 · see citing works
A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity
Shi, S. Y., Lu, Y., Liu, Z., Stevens, J. L., Murawsky, C. M., Wilson, V., Hu, Z., Richards, W. G., Michaels, M. L., Zhang, J., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.001752 · Cited by 32 · see citing works
Ji, F., Liu, Y., Hao, J., Wang, L., Dai, M.-J., Shen, G.-F., & Yan, X. (2019) · Aging · doi:10.18632/aging.102293 · Cited by 31 · see citing works
Fibroblast growth factor 21 as a potential master regulator in metabolic disorders
Velingkar, A., Vuree, S., Prabhakar, P. K., Kalashikam, R. R., Banerjee, A., & Kondeti, S. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00244.2022 · Cited by 32 · see citing works
Yin, J., Bao, L., Tian, H., Wang, Q., Gao, X., & Yao, W. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13499 · Cited by 30 · see citing works
Roh, E., Hwang, S. Y., Yoo, H. J., Baik, S. H., Cho, B., Park, Y. S., Kim, H. J., Lee, S., Kim, B., Jang, H. C., et al. (2021) · Age and Ageing · doi:10.1093/ageing/afab178 · Cited by 31 · see citing works
Do, P. T., Chuang, D., Wu, C.-C., Huang, C.-Z., Chen, Y., Kang, S.-J., Chiang, Y. H., Hu, C., & Chen, K. (2023) · Translational Stroke Research · doi:10.1007/s12975-023-01196-8 · Cited by 29 · see citing works
Singh, R., Pervin, S., Lee, S., Kuo, A., Grijalva, V. R., David, J., Vergnes, L., & Reddy, S. T. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s159315 · Cited by 29 · see citing works
Fibroblast growth factor 21 and exercise-induced hepatic mitochondrial adaptations
Fletcher, J. A., Linden, M. A., Sheldon, R. D., Meers, G. M.-E., Morris, E. M., Butterfield, A. M., Perfield, J. W., Thyfault, J. P., & Rector, R. S. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00355.2015 · Cited by 28 · see citing works
Xue, B., Xiao, X., Yu, T., Xiao, X., Xie, J., Ji, Q., Wang, L., Na, T., Meng, S., 耿培亮, et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02205-z · Cited by 27 · see citing works
Hepatocyte β‐Klotho regulates lipid homeostasis but not body weight in mice
Kobayashi, K., Tanaka, T., Okada, S., Morimoto, Y., Matsumura, S., Manio, M. C. C., Inoue, K., Kimura, K., Yagi, T., Saito, Y., et al. (2015) · The FASEB Journal · doi:10.1096/fj.15-274449 · Cited by 26 · see citing works
Translational Pharmacology and Physiology of Brown Adipose Tissue in Human Disease and Treatment
Larson, C. J. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_184 · Cited by 25 · see citing works
The fibroblast growth factor system in cognitive disorders and dementia
Zhai, W., Zhang, T., Jin, Y., Huang, S., Xu, M., & Pan, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1136266 · Cited by 25 · see citing works
Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects
Watanabe, H., Miyahisa, M., Chikamatsu, M., Nishida, K., Minayoshi, Y., Takano, M., Ichimizu, S., Kobashigawa, Y., Morioka, H., Maeda, H., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.036 · Cited by 24 · see citing works
Hao, L., Huang, N. K., Ito, K., Sae‐tan, S., Lambert, J. D., & Ross, A. C. (2016) · Journal of Nutrition · doi:10.3945/jn.115.216572 · Cited by 24 · see citing works
Roux-en-Y gastric bypass surgery is effective in fibroblast growth factor-21 deficient mice
Morrison, C. D., Zheng, H., Mumphrey, M. B., Townsend, R. L., Münzberg, H., Ye, J., & Berthoud, H. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.08.005 · Cited by 23 · see citing works
Chang, H. H., Chen, P. S., Cheng, Y. W., Wang, T., Yang, Y. K., & Lu, R. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx093 · Cited by 24 · see citing works
Majeed, M. A., Majeed, S., Nagabhushanam, K., Lawrence, L., & Mundkur, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-64293-w · Cited by 23 · see citing works
Lewis, J. E., Monnier, C., Marshall, H. J., Fowler, M. J., Green, R., Cooper, S., Chiotellis, A., Luckett, J., Perkins, A. C., Coşkun, T., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.009 · Cited by 21 · see citing works
Giragossian, C., Vage, C., Li, J., Pelletier, K. B., Piche‐Nicholas, N., Rajadhyaksha, M., Liras, J. L., Logan, A., Calle, R. A., & Weng, Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061713 · Cited by 20 · see citing works
Tapía, P., Fernández‐Galilea, M., Robledo, F., Mardones, P., Galgani, J. E., & Cortés, V. (2017) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12389 · Cited by 20 · see citing works
Maio, G. D., Alessio, N., Demirsoy, İ. H., Peluso, G., Perrotta, S., Monda, M., & Bernardo, G. D. (2021) · Cells · doi:10.3390/cells10020403 · Cited by 19 · see citing works
Ahnak deficiency attenuates high-fat diet-induced fatty liver in mice through FGF21 induction
Kim, Y. N., Shin, J. H., Kyeong, D. S., Cho, S. Y., Kim, M., Lim, H. J., Jimenez, M. R. R., Kim, I. Y., Lee, M., Bae, Y. S., et al. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00573-3 · Cited by 19 · see citing works
Atypical Diabetes: What Have We Learned and What Does the Future Hold?
Stone, S., Balasubramanyam, A., & Posey, J. E. (2024) · Diabetes Care · doi:10.2337/dci23-0038 · Cited by 18 · see citing works
- Authors
- Gimeno, R. E., & Moller, D. E.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Gimeno, Ruth E.
- Moller, David E.
- ORCID
- Moller, David E.
- Venue
- Trends in Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 25
- Issue
- 6
- Pages
- 303-311
- ISSN
- 1043-2760 (ISSN-L)
- OpenAlex
- W2038863889
- Cited by
- 163
- References
- 82
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 7 · 2023: 8 · 2022: 8 · 2021: 14 · 2020: 15 · 2019: 14 · 2018: 13 · 2017: 16 · 2016: 36 · 2015: 21 · 2014: 3
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Trends in Endocrinology and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21, type 2 diabetes, obesity, metabolic disorders, antidiabetic therapy, hypolipidemic effect, weight loss, insulin sensitivity, fatty acid oxidation, energy expenditure, adipose tissue, liver, brain, non-human primates
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Energy Metabolism, Fibroblast Growth Factors, Humans, Metabolic Diseases, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review